LYSOSOMAL ACID LIPASE ACTIVITY CORRELATES WITH IMMUNE AND BIOCHEMICAL BIOMARKERS METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE BETTER EFFECT ON METABOLIC SYNDROME PATIENTS, PRELIMINARY STUDY

Introduction and Objectives

Pathophysiology of Metabolic dysfunction- associated steatotic liver disease (MASLD) included dyslipidemia and genetic factors.

Lysosomal Acid Lipase (LAL) plays a key role in intra-cellular cholesterol trafficking. LAL activity is reduced on MASLD patients. LAL deficiency caused alterations in lipid and glucose metabolism, inflammation, myeloid cells function, and liver functions.

The main objective of these study was evaluating the biochemical profile, and immunological characteristics related to LAL activity on MASLD patients.

Patients and Methods

Patients were evaluated by hepatic elastography, LAL activity, and, saliva was collected to analyzed immune profile by Fourier-transformed infrared spectroscopy (FTIR) at IgG(1560-1464), IgA(1285-1237cm^-1), and IgM(1160-1028 cm^-1), IFN-γ(1061-1044 cm^-1), TNF-α(1243-1217 cm^-1), IL-6(1436-1428cm^-1). Anthropometric, clinical, and biochemical parameters were collected. Correlation analysis were employed.

Results

Total 12 patients with MASLD, most female 8 (66.7 %), 3 (25%) steatosis S1, 2 (16.7 %) steatosis S2 and 7 (58.3) steatosis S3, 7 (58.3) had prediabetes, 2 (16.7 %) had DM2, 1 (8.3 %) had hypertension, 8 (66.7%) had high triglyceride levels, and 6 (50 %) had low levels of HDL-cholesterol.

The median levels of Lysosomal Acid Lipase Activity were 0.43 ± 0.19nmol/punch/hour, there are not correlation with CAP or LSM but there are significant inverse correlation with haemoglobin, creatinine, uric acid, total bilirubin, indirect bilirubin, CH₃, C=O, IL-6 and IL1β; and a positive correlation with leukocytes, lymphocytes and platelets, lipid oxidation and serum carbonyl ratio.

Conclusions

MASLD patients has a low levels of LAL activity according with literature, and the LAL activity showed correlation with immune biomarkers and lipid changes on sera and saliva.

Conflict of interest: Yes, the AstraZeneca laboratory provided the kits for taking samples for the timely detection of lysosomal acid lipase deficiency (LAL-D).